Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc's Investigational Grass Sublingual Allergy Immunotherapy Tablet Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study


Saturday, 9 Nov 2013 12:00pm EST 

Merck & Co Inc announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Results showed that MK-7243 demonstrated significant improvement in Total Combined Score (TCS) averaged over the entire grass pollen season (the primary endpoint), which was the sum of the rhinoconjunctivitis daily symptom score (DSS) and the daily medication score (DMS), compared to placebo. Researchers will present findings at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore. This multicenter, double-blind, randomized, placebo-controlled, parallel-group study evaluated the efficacy and safety of the investigational MK-7243 sublingual tablet (2800 BAU) in 1,501 pediatric and adult patients (ages 5-65) with a clinical history of Timothy grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma (FEV1 ≥70% of predicted value). As baseline characteristics, 25% of patients in the study had asthma; patients with a history of severe asthma were excluded. Additionally, 85% of patients in the study were sensitized to multiple allergens. Patients received either MK-7243 or placebo once daily for at least 12 weeks prior to and during the grass pollen season. 

Company Quote

58.58
0.61 +1.05%
29 Jul 2014